Table 3.
Sleep Architecture Characteristics
| Sleep time, min | Dimdazenil (n = 367) | Placebo (n = 178) | P-value |
|---|---|---|---|
| Baseline | |||
| Sleep latency of stage N1 | 47.05 (42.31) | 42.07 (34.69) | 0.173 |
| Sleep latency of stage N2 | 51.58 (43.79) | 48.57 (36.06) | 0.426 |
| Sleep latency of stage N2 | 85.51 (59.32) | 83.06 (58.72) | 0.652 |
| Sleep latency of REM | 114.86 (60.41) | 114.00 (55.35) | 0.873 |
| Non-REM sleep time | |||
| Stage N1 | 41.31 (22.10) | 38.93 (22.62) | 0.243 |
| Stage N2 | 184.57 (42.34) | 182.62 (42.84) | 0.616 |
| Stage N3 | 50.65 (33.14) | 54.21 (34.90) | 0.248 |
| REM sleep time | 59.76 (21.06) | 58.73 (21.38) | 0.595 |
| Percent of sleep time for stage N1, % | 12.54 (6.63) | 11.94 (7.14) | 0.332 |
| Percent of sleep time for stage N2, % | 54.76 (11.10) | 54.13 (10.73) | 0.532 |
| Percent of sleep time for stage N3, % | 15.58 (10.76) | 16.34 (10.47) | 0.436 |
| Percent of sleep time for REM, % | 17.54 (6.17) | 17.28 (5.94) | 0.640 |
| Day 13/14 | |||
| Sleep latency of stage N1 | 30.73 (31.13) | 33.74 (38.75) | 0.335 |
| Sleep latency of stage N2 | 34.40 (32.70) | 38.04 (40.57) | 0.267 |
| Non-REM sleep time | |||
| Stage N1 | 39.76 (23.50) | 38.86 (24.16) | 0.678 |
| Stage N2 | 252.30 (58.63) | 205.26 (50.23) | <0.001 |
| Stage N3 | 50.58 (38.61) | 59.54 (38.15) | 0.012 |
| REM sleep time | 63.34 (25.91) | 72.82 (24.82) | <0.001 |
| Percent of sleep time for stage N1, % | 9.99 (6.12) | 10.75 (7.11) | 0.200 |
| Percent of sleep time for stage N2, % | 62.03 (11.23) | 54.79 (14.07) | <0.001 |
| Percent of sleep time for stage N3, % | 12.52 (9.38) | 16.05 (10.30) | <0.001 |
| Percent of sleep time for REM, % | 15.29 (5.69) | 19.31 (6.52) | <0.001 |
Variables expressed as mean (SD). REM, rapid eye movement.